Citation Information :
Solak Y, Selcuk NY, Gaipov A, Ucar R, Biyik Z, Acar K. Thrombotic thrombocytopenic purpura secondary to ABO group incompatible blood transfusion in a patient after cardiac surgery. Indian J Crit Care Med 2013; 17 (4):234-236.
The triggers of secondary thrombotic thrombopcytopenic purpura (TTP) include drug toxicity, radiation and high-dose chemotherapy, angioinvasive infections, surgery and acute graft versus host disease. TTP secondary to surgery have been reported in a number of cases. Most of the cases have been occurred after open heart surgery. Extensive endothelial damage is held responsible as the initiating mechanism in postoperative TTP cases. However, there is no report of secondary TTP describing development owing to ABO incompatible blood transfusion. Here, we describe a patient who developed TTP after transfusion of ABO incompatible blood during hospitalization for bypass surgery. We also propose a hypothesis which may account for the possible underlying mechanism.
Despotis GJ, Zhang L, Lublin DM. Transfusion risks and transfusion-related pro-inflammatory responses. Hematol Oncol Clin North Am 2007;21:147-61.
Stainsby D, Russell J, Cohen H, Lilleyman J. Reducing adverse events in blood transfusion. Br J Haematol 2005;131:8-12.
Stainsby D. Errors in transfusion medicine. Anesthesiol Clin North Am 2005;23:253-61, v.
Pineda AA, Brzica SM Jr., Taswell HF. Hemolytic transfusion reaction. Recent experience in a large blood bank. Mayo Clin Proc 1978;53:378-90.
Staropoli JF, Stowell CP, Tuncer HH, Marques MB. An inquiry into the relationship between ABO blood group and thrombotic thrombocytopenic purpura. Vox Sang 2009;96:344-8.
Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: All patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005;3:1432-6.
Zuberi L, Yerasuri D, Kuriakose P. Effect of blood group on idiopathic thrombotic thrombocytopenic purpura. J Clin Apher 2009;24:131-3.
Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int 2006;70:16-23.
Terrell DR, Motto DG, Kremer Hovinga JA, Lammle B, George JN, Vesely SK. Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion 2011;51:2237-43.
George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927-35.
Sadler JE. Thrombotic thrombocytopenic purpura: A moving target. Hematology Am Soc Hematol Educ Program 2006:415-20.
Foley SR, Webert K, Arnold DM, Rock GA, Clark WF, Barth D, et al. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney Int Suppl 2009;112:S55-8.
Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: A report of 12 cases and review of literature. J Clin Apher 2008;23:151-6.
Naqvi TA, Baumann MA, Chang JC. Post-operative thrombotic thrombocytopenic purpura: A review. Int J Clin Pract 2004;58:169-72.
